Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Rituximab 689Cyclophosphamide 614Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 228Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 175Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106Tacrolimus 105obinutuzumab 104Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Comparative Genomic Hybridization × Lymphoid × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡